期刊文献+

不同配比头孢噻肟与舒巴坦的体外抗菌活性 被引量:6

In vitro antibacterial activities of different formula cefotaxime/sulbactam
下载PDF
导出
摘要 目的研究不同配比的头孢噻肟/舒巴坦及头孢噻肟单剂对临床分离菌体外抗菌作用。方法测定644株细菌的最低抑菌浓度(MIC)、最低杀菌浓度(MBC),观察细菌接种量、培养基酸碱度和血清蛋白含量对体外药效学的影响。结果头孢噻肟/舒巴坦(1:1,2:1)对革兰阳性球菌MIC50为0.06~32mg·L^-1;对革兰阴性杆菌MIC90为0.25—32mg·L^-1,是头孢噻肟单剂的1/4~1/8。结论1:1,2:1配比的头孢噻肟/舒巴坦对绝大多数临床感染细菌有很强的抗菌活性,明显优于头孢噻肟单剂和头孢噻肟/舒巴坦其他配比。 Objective To study the in vitro antibacterial activities of cefotaxime and different formula of cefotaxime/sulbactam. Methods Minimal inhibitory concentrations ( MIC ) and the minimal bactericidal concentrations(MBC) were measured on 644 clinical isolates. The influences of the inoculum size, pH and concentrtion of serum protein on antibacterial activities of cefotaxime/sulbactam were observed. Results MIC50 of cefotaxime/sulbaetam ( 1 : 1,2: 1 ) against β- lactmases - producing gram - positive coccus was 0.06 - 32 mg·L^-1, MIC90 of cefotaxime/sulbactam ( 1: 1,2: 1 ) against gram - negative bacteria was 0.25 - 32 mg·L^-1 ,being 1/4-1/8 of that of cefotaxime alone. Conclusion Cefotaxime/sulbactam with 1: 1 and 2:1 ratio possesses high antibacterial activities against most clinical isolates. It's better than that of cefotaxime alone and cefotaxime/sulbactam with other ratios.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2006年第1期59-64,共6页 The Chinese Journal of Clinical Pharmacology
关键词 头孢噻肟/舒巴坦 体外抗菌活性 临床分离菌 cefotaxime/sulbactam in vitro antibacterial activity clinical isolate
  • 相关文献

参考文献5

二级参考文献6

共引文献9

同被引文献86

引证文献6

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部